Interestingly, studies conducted in murine models of arthritis have shown that CD39 blockade and decreased adenosine generation reverse the therapeutic effect of MTX, while non-responder patients express lower pre-treatment levels of CD39/ENTPD1 [44]. The gene discussed is ENTPD1; the disease is arthritic joint disease.